Legal Notes

Exeltis USA, Inc., a Delaware corporation with a registered office at 180 Park Ave, Suite 101, Florham Park, NJ 07932 ("EXELTIS") maintains this site (the "Site") for general information and communication purposes only. All the information on this Site is published in good faith. Please be informed that your access, browse, and use of the Site is subject to the following Terms and Conditions ("Terms and Conditions") and all applicable laws.

Terms and Conditions

These Terms and Conditions govern access to and use of the Site. They do not relate to the purchase of any product displayed on the Site. By using this Site, you accept these Terms and Conditions in full.

Everything contained in this Site is proprietary information of EXELTIS, which owns the intellectual property rights and the material on the Site. Subject to the license below, all these intellectual property rights are reserved. You may not use or link any information or material in this Site without the written permission of EXELTIS, except as expressly provided in these Terms and Conditions or with the text of the Site.

You may freely browse the Site, but your accessing, downloading, and/or using of any information from this Site, including, but not limited to, any text, images, audio, and video is limited to your own personal use.

Nothing in this Site shall be deemed to constitute, by implication or otherwise, the grant of any license or right to use any EXELTIS intellectual property rights and/or any information or materials herein contained. Therefore, you are not allowed to, without written permission of EXELTIS, distribute, modify, transmit, reuse, repost, or use the information contained herein for any commercial purpose, unless expressly provided in these Terms and Conditions or within the text of the Site.

EXELTIS maintains this Site for general information and communication purposes only, using reasonable efforts to include accurate and up-to-date information. EXELTIS makes no warranties or representations as to the accuracy of the information and materials on the Site.

The product information herein contained is not intended to provide complete medical information or medical advice. EXELTIS shall not be held responsible for any action taken that is based on the information presented on the Site, and you agree that access and use of the Site, as well as the information and materials herein contained, is at your own risk. EXELTIS assumes no liability or responsibility for any errors or omissions in the content of the Site.

The information on the Site should be carefully evaluated by you and your medical doctor or healthcare professional. EXELTIS does not provide personal medical diagnosis or treatment advice. You should always obtain complete medical information about the products you take by discussing the appropriate use of any product directly with your medical doctor or healthcare professional.

EXELTIS neither warrants nor represents that your use of any information or materials displayed on the Site will not infringe rights of third parties. This Site may contain information on worldwide products, not all of which are available in every country. A reference to a product on this Site does not imply that such a product is or will be available in your country. You should not understand anything on this Site as a promotion or advertisement for any product or for the use of any product if not available or authorized in your country.

Your use of and/or browsing on the Site is at your own risk. To the extent permitted by law, neither EXELTIS nor any of its parents, subsidiaries, divisions, affiliates, agents, representatives, or licensors shall be liable to you and/or anyone else for any loss or injury or any direct, indirect, incidental, consequential, special, punitive, or similar damages arising out of your access or use of, or your inability to access or use, this Site.

The Site is provided on an "as is" basis. Everything on the Site is provided to you without warranty of any kind, express or implied, including, but not limited to, the implied warranties of merchantability, fitness for a particular purpose, or non-infringement.

With the sole exception of the Privacy Policy hereinafter included, any information or materials you transmit to the Site is and will be treated as non-confidential and non-proprietary.

This Site uses cookies. By using this Site and agreeing to these Terms and Conditions, you consent to the EXELTIS use of cookies in accordance with the terms of the EXELTIS Privacy Policy ("Privacy Policy").

Should the site include links to third-party sites, the same are provided for your interest or convenience. EXELTIS does not control or endorse any of these third-party websites, and linking is not intended to imply, nor does it create, any association between EXELTIS and the parties involved in such websites. Furthermore, EXELTIS does not control the policies, practices, or content of these third-party websites and cannot represent or warrant that their policies, practices, or content will comply with these Terms and Conditions. If you use any links to websites not maintained by EXELTIS, you do so at your own risk.

EXELTIS also assumes no responsibility, and shall not be liable for any damages or viruses that may affect your computer equipment or other property on account of your access to, use of, or browsing of the Site or your downloading of any materials, data, text, images, video, or audio from the Site.

EXELTIS may at any time revise these Terms and Conditions by updating this posting. You are bound by any such revisions and should therefore periodically visit this page to review the current Terms and Conditions to which you are bound.

These Terms of Use shall be governed by and construed in accordance with the laws of the State of New Jersey, USA, as they apply to agreements made and solely performed therein. Disputes arising hereunder shall be exclusively subject to the jurisdiction of the federal courts of the United States of America of New Jersey, and jurisdiction therefore shall rest solely in New Jersey, USA.

INDICATIONS AND USAGE

Benznidazole Tablets, a nitroimidazole antimicrobial, is indicated in pediatric patients 2 to 12 years of age for the treatment of Chagas disease (American trypanosomiasis) caused by Trypanosoma cruzi.

This indication is approved under accelerated approval based on the number of treated patients who became Immunoglobulin G (IgG) antibody negative against the recombinant antigens of T cruzi. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.

IMPORTANT SAFETY INFORMATION

Contraindications

Benznidazole Tablets are contraindicated in patients with a history of hypersensitivity reactions to benznidazole or other nitroimidazole derivatives. Reactions have included severe skin and soft tissue reactions. Benznidazole Tablets is also contraindicated in patients who have taken disulfiram within the last two weeks. Psychotic reactions may occur in patients who are using benznidazole and disulfiram concurrently. Consumption of alcoholic beverages or products containing propylene glycol is contraindicated in patients during and for at least 3 days after therapy with Benznidazole Tablets. A disulfiram-like reaction (abdominal cramps, nausea, vomiting, headaches, and flushing) may occur due to the interaction between alcohol or propylene glycol and benznidazole. Benznidazole Tablets are contraindicated in patients with Cockayne syndrome. Severe irreversible hepatotoxicity/acute liver failure with fatal outcomes have been reported after initiation of metronidazole, another nitroimidazole drug, structurally related to benznidazole in patients with Cockayne syndrome.

Warnings and Precautions

Potential for Genotoxicity and Carcinogenicity: Genotoxicity has been demonstrated in humans, in vitro in several bacterial species and mammalian cell systems, and in vivo in rodents. A study evaluating the cytogenetic effect of benznidazole in pediatric patients ranging from 11 months to 11 years of age (the safety and effectiveness of Benznidazole Tablets in patients less than 2 years old has not been established) with Chagas disease demonstrated a two-fold increase in chromosomal aberrations. In pediatric patients with Chagas disease who were treated with benznidazole, the median incidence of micronucleated interphase lymphocytes in 20 patients increased two-fold compared to pre-dose values. In the same study, the mean incidence of chromosomal aberrations in 10 patients also increased two-fold compared to pre-dose values.

Carcinogenicity has been observed in mice and rats treated chronically with nitroimidazole agents, which are structurally similar to benznidazole. Similar data have not been reported for benznidazole. It is not known whether benznidazole is associated with carcinogenicity in humans.

Embryo-Fetal Toxicity: Based on animal studies, Benznidazole Tablets can cause fetal harm when administered to a pregnant woman. Advise pregnant women of the potential risk to a fetus. Pregnancy testing is recommended for women of reproductive potential prior to Benznidazole Tablets therapy. Advise women of reproductive potential to use effective contraception during treatment with Benznidazole Tablets and for 5 days after the last dose.

Hypersensitivity Skin Reactions: Serious skin and subcutaneous disorders, including acute generalized exanthematous pustulosis (AGEP), toxic epidermal necrolysis (TEN), erythema multiforme, and eosinophilic drug reactions, have been reported with benznidazole. Discontinue treatment at first evidence of these serious cutaneous reactions. Extensive skin reactions, such as rashes, have also been reported. Most cases occurred after approximately 10 days of treatment with benznidazole. Most rashes resolved with treatment discontinuation. In case of skin reactions presenting with additional symptoms or signs of systemic involvement, such as lymphadenopathy, fever, and/or purpura, discontinuation of treatment is recommended.

Central and Peripheral Nervous System Effects: Benznidazole Tablets can cause paresthesia or symptoms of peripheral neuropathy that may take several months to resolve. Headache and dizziness have been reported. In cases where neurological symptoms occur, immediate discontinuation of treatment is recommended. In most cases, symptoms occur late in the course of treatment.

Hematological Manifestations of Bone Marrow Depression: There have been reports of hematological manifestations of bone marrow depression, such as neutropenia, thrombocytopenia, anemia, and leukopenia, which resolved after treatment discontinuation. Patients with hematological manifestations of bone marrow depression must take Benznidazole Tablets only under strict medical supervision. Monitor complete blood count. Total and differential leukocyte counts are recommended before, during, and after therapy.

Adverse Reactions

The most common adverse reactions observed were abdominal pain (25%), rash (16%), decreased weight (13%), and headache (7%).

Use in Specific Populations

Lactation Risk: Limited published literature based on breast milk sampling reports that benznidazole is present in human milk. There are no reports of adverse effects on the breastfed infant and no information on the effects of benznidazole on milk production. Because of the potential for serious adverse reactions, and transmission of Chagas disease, advise patients that breastfeeding is not recommended during treatment with Benznidazole Tablets.

Male Infertility: Based on findings in rodents, Benznidazole Tablets may impair fertility in males of reproductive potential. It is not known whether effects on fertility are reversible.

Before prescribing Benznidazole Tablets and for further safety information, please read the full Prescribing Information here.

Indications and Usage and Important Safety Information

INDICATIONS AND USAGE

Benznidazole Tablets, a nitroimidazole antimicrobial, is indicated in pediatric patients 2 to 12 years of age for the treatment of Chagas disease (American trypanosomiasis) caused by Trypanosoma cruzi.

This indication is approved under accelerated approval based on the number of treated patients who became Immunoglobulin G (IgG) antibody negative against the recombinant antigens of T cruzi. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.